Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 16, 2014; 2(6): 194-200
Published online Jun 16, 2014. doi: 10.12998/wjcc.v2.i6.194
Published online Jun 16, 2014. doi: 10.12998/wjcc.v2.i6.194
Therapeutic strategies for targeting the ovarian tumor stroma
Song Yi Ko, Honami Naora, Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Author contributions: Ko SY and Naora H contributed equally to this work, generated the figure and wrote the manuscript.
Supported by Cancer and Prevention Research Institute of Texas grant, NO. RP120390 (HN); and United States National Institutes of Health grant, NO. CA141078 (HN)
Correspondence to: Honami Naora, PhD, Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 108, Houston, TX 77030, United States. hnaora@mdanderson.org
Telephone: +1-713-5634222 Fax: +1-713-7943270
Received: December 20, 2013
Revised: March 23, 2014
Accepted: May 13, 2014
Published online: June 16, 2014
Processing time: 182 Days and 18.1 Hours
Revised: March 23, 2014
Accepted: May 13, 2014
Published online: June 16, 2014
Processing time: 182 Days and 18.1 Hours
Core Tip
Core tip: Despite advances in clinical management, advanced-stage ovarian cancer is still rarely cured by conventional chemotherapy. Substantial efforts have been directed to developing new therapies that target ovarian cancer cells. However, recent studies have revealed important roles of a variety of stromal cells in driving the aggressive behavior of ovarian cancer. Here, we discuss: (1) the significance of three major types of stromal cells in the progression of ovarian cancer; (2) how receptor/ligand-mediated interactions between ovarian cancer cells and stromal cells serve as focal points for therapeutic intervention; and (3) key examples of new-generation agents that target stromal cells.